糖尿病慢性肢体威胁性缺血患者膝下血管内血运重建的预后预测因素
本研究纳入203例因慢性肢体威胁性缺血接受膝下血管内血运重建的连续糖尿病患者,共成功开通437条靶血管。Kaplan-Meier分析显示1年和2年免截肢生存率分别为74%和63%。Cox回归表明围术期高毛细血管血糖是再狭窄的独立预测因素,术后双联抗血小板治疗与更好的免截肢生存相关,基线eGFR较高与更好的免截肢生存显著相关。
要点
- 围术期高毛细血管血糖是糖尿病膝下血运重建后再狭窄的独立预测因素。
- 术后双联抗血小板治疗与更好的免截肢生存和免于主要肢体不良事件相关。
- 基线eGFR较高与更好的免截肢生存显著相关。
核心结论
- 围术期血糖控制不佳与糖尿病膝下血运重建后再狭窄发生率较高相关。
- 双联抗血小板治疗在该组患者中与更好的结局相关。
研究设计与样本
- 连续纳入因慢性肢体威胁性缺血接受膝下血管内血运重建的糖尿病患者。
- 共203例患者,成功开通437条膝下靶血管。
- 收集人口学、手术细节、每日毛细血管血糖和血红蛋白A1C水平,采用Kaplan-Meier和Cox回归分析。
主要发现
- 1年免截肢生存率为74%(标准误3.3%),2年为63%(标准误3.7%)。
- 1年一期通畅率为61%(标准误4.2%),2年为50%(标准误4.9%)。
- 1年辅助一期通畅率为69%(标准误5.2%),2年为55%(标准误6.1%)。
- 1年二期通畅率为71%(标准误3.8%),2年为59%(标准误4.1%)。
- Cox回归显示围术期高毛细血管血糖是二分类再狭窄的独立预测因素(HR 1.49;95%CI 1.31-1.78;P=.015)。
关键数值与推荐
- 术后双联抗血小板治疗是免截肢生存的独立预测因素(HR 1.69;95%CI 1.04-2.75;P=.033)。
- 术后双联抗血小板治疗与免于主要肢体不良事件独立相关(HR 1.96;95%CI 1.16-3.27;P=.023)。
- 基线eGFR与更好的免截肢生存显著相关(HR 0.52;95%CI 0.31-0.87;P=.014)。
临床怎么用
- 对糖尿病膝下血运重建患者应重视围术期血糖管理以降低再狭窄风险。
- 可考虑术后双联抗血小板治疗以改善免截肢生存和减少主要肢体不良事件。
- 评估基线eGFR有助于风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The incidence of chronic limb-threatening ischemia in diabetic patients is increasing. The factors influencing outcome after infrapopliteal revascularization in these patients are largely unknown. Therefore, this study aims to identify the impact of perioperative glucose control on the long-term outcomes in this patient cohort, and furthermore to identify other factors independently associated with outcome. METHODS: Consecutive diabetic patients undergoing infrapopliteal endovascular revascularization for chronic limb-threatening ischemia were identified. Patients' demographics, procedural details, daily capillary blood glucose, and hemoglobin A1C levels were collected and analyzed against the study end points using Kaplan-Meier and Cox regression analysis. RESULTS: A total of 437 infrapopliteal target vessels were successfully crossed in 203 patients. Amputation-free survival by Kaplan-Meier (estimate (standard error)%) was 74 (3.3)% and 63 (3.7)%, primary patency was 61 (4.2)% and 50 (4.9)%, assisted primary patency was 69 (5.2)% and 55 (6.1)%, and secondary patency was 71 (3.8)% and 59 (4.1)% at 1 year and 2 years, respectively. Cox regression analysis showed high perioperative capillary blood glucose levels to be an independent predictor of binary restenosis (hazard ratio [HR], 1.49; 95% confidence interval [CI], 1.31-1.1.78; P = .015). Postprocedural dual-antiplatelet therapy was found to be an independent predictor of amputation-free survival (HR, 1.69; 95% CI, 1.04-2.75; P = .033), and freedom from major adverse limb events (HR: 1.96; 95% CI, 1.16-3.27; P = .023) and baseline estimated glomerular filtration rate was significantly associated with better amputation-free survival (HR, 0.52; 95% CI, 0.31-0.87; P = .014). CONCLUSIONS: Poor perioperative glycemic control is associated with a higher incidence of restenosis after infrapopliteal revascularization in diabetic patients. Dual antiplatelet therapy is associated with better outcomes in this group.
引用
- Yap T, Silickas J, Weerakkody R, et al. Predictors of outcome in diabetic patients undergoing infrapopliteal endovascular revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2021. PMID: 34634414. doi:10.1016/j.jvs.2021.09.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。